Most employers treat metabolic risk as a chemistry problem.

They track A1C. They monitor triglycerides. They debate GLP-1 coverage. They review pharmacy trend lines. And many of those interventions “work.” Weight drops. Labs improve. Claims stabilize.

But almost no one asks the harder question:

What happens when the intervention stops?

In this episode of Healthy Business Matters, Dr. Andrew White argues that metabolic dysfunction doesn’t begin with A1C — it begins when movement becomes expensive.

When bending hurts.

When knees swell.

When sleep is disrupted by pain.

When daily activity quietly declines.

Because insulin sensitivity isn’t primarily a lab issue. It’s a muscle issue.

Muscle is the largest site of glucose disposal in the body. When movement capacity erodes, metabolic stabilit ...